ClinVar Miner

Submissions for variant NM_003002.4(SDHD):c.33C>A (p.Cys11Ter)

dbSNP: rs104894309
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000221327 SCV000274061 pathogenic Hereditary cancer-predisposing syndrome 2022-05-06 criteria provided, single submitter clinical testing The p.C11* pathogenic mutation (also known as c.33C>A), located in coding exon 1 of the SDHD gene, results from a C to A substitution at nucleotide position 33. This changes the amino acid from a cysteine to a stop codon within coding exon 1 (p.C11*). This mutation has been reported in multiple individuals diagnosed with pheochromocytoma(s) and/or extra-adrenal paraganglioma(s) (Neumann HP et al. N. Engl. J. Med. 2002 May;346(19):1459-66; Peczkowska M et al. J. Clin. Endocrinol. Metab. 2008 Dec;93(12):4818-25; Michaowska I et al. Neuroendocrinology. 2015 Mar;101:321-30; Michaowska I et al. Kardiochir Torakochirurgia Pol. 2016 Sep;13:276-282). Peczkowaka and colleagues analyzed numerous p.C11* carrier families ascertained through the European-American PGL-PCC registry. In this series, the penetrance of head and neck PGLs in mutation carriers was 100% by age 54 and haplotype analysis data supported p.C11* as a founder mutation of Polish origin (Peczkowska M et al. J. Clin. Endocrinol. Metab. 2008 Dec;93(12):4818-25). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV002228012 SCV000645369 pathogenic Carney-Stratakis syndrome; Pheochromocytoma; Paragangliomas with sensorineural hearing loss; Cowden syndrome 3 2022-10-10 criteria provided, single submitter clinical testing ClinVar contains an entry for this variant (Variation ID: 6915). For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with pheochromocytoma and/or paraganglioma (PMID: 12000816, 18826997, 29386252). It is commonly reported in individuals of Polish ancestry (PMID: 12000816, 18826997, 29386252). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Cys11*) in the SDHD gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHD are known to be pathogenic (PMID: 19454582, 19802898).
Institute of Human Genetics, University of Leipzig Medical Center RCV000007324 SCV002044437 pathogenic Pheochromocytoma 2021-12-09 criteria provided, single submitter clinical testing Criteria applied: PVS1, PS4_MOD, PM2_SUP
MGZ Medical Genetics Center RCV002288472 SCV002580586 pathogenic Paragangliomas 1 2021-12-28 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV002288472 SCV004189826 pathogenic Paragangliomas 1 2023-08-29 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.
OMIM RCV000007324 SCV000027522 pathogenic Pheochromocytoma 2002-05-09 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.